UK funds Domainex for cancer drug development
The new drug will inhibit two protein kinase enzymes, TBK1 and IKKe, which will suppress the growth of certain cancer cell lines. The project aims to identify a
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.